Risk factors, prognostic predictors, and nomograms for pancreatic cancer patients with initially diagnosed synchronous liver metastasis

doi:10.4251/wjgo.v15.i1.128

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5115)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series, Tables (1-3) series.

Item

Count

PDF

186

WORD

HTML

1962

Figures (1-7)

324

Tables (1-3)

345

Sum=2863

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

256

Download

762

Sum=1018

Publishing Process of This Article

Item

Count

Browse

239

Download

995

Sum=1234

Jan 15, 2023 (publication date) through Apr 24, 2025

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jan 15, 2023; 15(1): 128-142
Published online Jan 15, 2023. doi: 10.4251/wjgo.v15.i1.128

Table 2 Univariate and multivariate logistic analyses of liver metastasis in pancreatic cancer patients, n (%)

Variable	Levels	Without LM (n = 14608)	With LM (n = 7698)	Univariate analysis (OR, 95%CI)	Multivariate analysis (OR, 95%CI)
Age at diagnosis (yr)	≤ 70	8783 (60.1)	5032 (65.4)
Age at diagnosis (yr)	> 70	5825 (39.9)	2666 (34.6)	0.80 (0.75-0.85, P < 0.001)	0.72 (0.68-0.77, P < 0.001)
Sex	Female	7393 (50.6)	3485 (45.3)
Sex	Male	7215 (49.4)	4213 (54.7)	1.24 (1.17-1.31, P < 0.001)	1.16 (0.89-1.23, P = 0.056)
Race	White	11590 (79.3)	6048 (78.6)
	Black	1730 (11.8)	1047 (13.6)	1.16 (1.07-1.26, P < 0.001)	1.07 (0.97-1.17, P = 0.186)
	Other	1288 (8.8)	603 (7.8)	0.90 (0.81-0.99, P = 0.036)	0.93 (0.83-1.04, P = 0.228)
Primary site	Head	8939 (61.2)	3003 (39)
	Body/tail	3604 (24.7)	3212 (41.7)	2.65 (2.49-2.83, P < 0.001)	2.30 (2.14-2.47, P < 0.001)
	Other	2065 (14.1)	1483 (19.3)	2.14 (1.98-2.31, P < 0.001)	1.76 (1.61-1.92, P < 0.001)
Histology	Adenocarcinoma	9394 (64.3)	5867 (76.2)
	Neuroendocrine carcinoma	640 (4.4)	411 (5.3)	1.03 (0.90-1.17, P = 0.670)	1.28 (1.10-1.49, P = 0.001)
	Other	4574 (31.3)	1420 (18.4)	0.50 (0.46-0.53, P < 0.001)	0.61 (0.56-0.66, P < 0.001)
Pathological grade	Well/moderate	4727 (32.4)	799 (10.4)
	Poor/anaplastic	2476 (16.9)	919 (11.9)	2.20 (1.97-2.44, P < 0.001)	2.26 (2.01-2.53, P < 0.001)
	Unspecific	7405 (50.7)	5980 (77.7)	4.78 (4.40-5.19, P < 0.001)	4.23 (3.86-4.64, P < 0.001)
T stage	T1	1131 (7.7)	245 (3.2)
	T2	2901 (19.9)	2653 (34.5)	4.22 (3.65-4.90, P < 0.001)	1.53 (0.89-1.86, P = 0.080)
	T3	7325 (50.1)	2402 (31.2)	1.51 (1.31-1.75, P < 0.001)	0.81 (0.64-1.02, P = 0.054)
	T4	3019 (20.7)	1411 (18.3)	2.16 (1.86-2.52, P < 0.001)	0.72 (0.56-1.01, P = 0.051)
	TX	232 (1.6)	987 (12.8)	9.4 (6.4-9.7, P < 0.001)	7.18 (5.52-9.35, P < 0.001)
LN metastasis	No	8213 (56.2)	4046 (52.6)
LN metastasis	Yes	6395 (43.8)	3652 (47.4)	1.16 (1.10-1.23, P < 0.001)	1.38 (1.30-1.47, P < 0.001)
Tumor size (cm)	< 2	1966 (13.5)	460 (6)
	2-4	6800 (46.5)	2939 (38.2)	1.85 (1.66-2.06, P < 0.001)	1.29 (1.08-1.55, P = 0.006)
	> 4	5842 (40)	4299 (55.8)	3.15 (2.82-3.51, P < 0.001)	2.05 (1.71-2.46, P < 0.001)

OR: Odds ratio; CI: Confidence interval; LN: Lymph node; LM: Liver metastasis.

Citation: Cao BY, Tong F, Zhang LT, Kang YX, Wu CC, Wang QQ, Yang W, Wang J. Risk factors, prognostic predictors, and nomograms for pancreatic cancer patients with initially diagnosed synchronous liver metastasis. World J Gastrointest Oncol 2023; 15(1): 128-142
URL: https://www.wjgnet.com/1948-5204/full/v15/i1/128.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i1.128